Models for estimating an individual's risk of having or developing a disease are abundant in the medical literature, yet many do not meet the methodological standards that have been set to maximise generalisability and utility. This paper presents an overview of ten steps from the conception of the study to the implementation of the risk model and discusses common pitfalls. We discuss crucial aspects of study design, data collection, model development and performance evaluation, and discuss how to bring the model to clinical practice.
Introduction
In recent years we have seen an increasing number of papers about risk models. 1 The term 'risk model' refers to any model that predicts the risk that a condition is present (diagnostic) or will develop in the future (prognostic). 2 Risk prediction is usually performed using multivariable models that aim to provide reliable predictions in new patients. 3, 4 Risk models may aid clinicians in making treatment decisions based on patient-specific measurements. In that sense risk models may foster, promote, stimulate, strengthen or encourage personalised medicine, and enhance shared decision-making. 5 To maximise their potential, it is imperative that risk models are developed carefully and validated rigorously. Unfortunately, reviews have demonstrated that methodological and reporting standards are often not met. 1, [6] [7] [8] We present a 'road map' with ten steps to summarise the process from the conception of a risk model to its final implementation. We address these steps one by one and highlight common pitfalls (Table 1) . Technical details on the methods for the development and evaluation of risk models are presented in boxes for the interested reader.
Case studies
Two case studies are presented that illustrate the ten steps. The first, presented in the main text below, involves the development of the ADNEX model for the preoperative diagnosis of suspicious ovarian tumours. 9 The ADNEX model predicts whether a tumour is benign, borderline malignant, stage I cancer, advanced stage cancer, or secondary metastatic cancer. The second case study, presented in Supplementary Table S1 , deals with the external validation of two existing models for the prediction of successful vaginal delivery after a previous caesarean section. 10 Step I: Before getting started
It is pivotal to define up-front what clinical purpose the risk model should serve, 11 as well as the target population and clinical setting. A mismatch with clinical needs is not uncommon and makes the model useless (Table 1 , pitfall 1). Next, ask whether a new model is needed. Often models for the same purpose already exist. 1 If so, the characteristics of these models should be checked (e.g., the clinical setting and included predictors), and the extent to which these models have been validated. Search strategies for finding relevant existing risk models are available. 2, 12 Systematic reviews indicate that models are often developed in vain because there was no clear clinical need, models already existed and/or existing models had not yet been the subject of validation studies. [13] [14] [15] Case study
Existing prediction models for ovarian tumour diagnosis focus on the general prediction of malignancy. 16 A model that preoperatively predicts the risk for subgroups of malignant tumours is clinically relevant because optimal management varies with subgroup. The target population involves women presenting in secondary or tertiary care with an adnexal (ovarian, para-ovarian or tubal) mass that is selected for surgery.
Step II: Study design and set-up
We encourage investigators to discuss the study set-up beforehand, and to write a protocol that covers each of the ten steps. 17 For complete transparency, consider publishing the protocol and registering the study. 18 The preferred design is a cross-sectional cohort study for diagnostic and a longitudinal cohort study for prognostic risk models, ideally where data are collected with the primary aim of developing the risk model. The latter is often referred to as a prospective study, 2, 19 as opposed to a retrospective study, for which data already exist for another purpose, although we advise caution with these terms as their definitions are not consistent. 20 Box S1 presents alternative designs and data sources with their limitations. 2, [21] [22] [23] The patient sample should be representative of the intended target population for the model. In order to prevent bias, a consecutive sample of patients is preferred. To enhance model generalisability and transportability, multicentre data collection is recommended. It is important to carefully identify the predictor variables for inclusion in the study, such as established risk factors, variables that are easy to collect, 24 and promising variables of which the predictive value has yet to be established. Variable and outcome definitions should be standardised in advance, and measurement error avoided (see Box S1). [25] [26] [27] [28] Finally, bear in mind that the potential predictors should be available when the risk model will be used during patient care. For example, when predicting the risk of a birth defect at the nuchal scan, do not consider birth weight as a predictor.
However carefully the study is designed, data are rarely complete. A common mistake is to exclude patients with missing data (reducing the sample size), and perform the analysis only on complete cases (Table 1 , pitfall 2). Because there is usually a reason for missing values, this may lead to a biased sample and hence a model with poor generalisability. 29 The preferred approach is to replace ('impute') the missing data with sensible values. Preferably several plausible values are imputed ('multiple imputation') to acknowledge that imputed values are themselves estimates and thus uncertain. 30, 31 Further details on imputation are presented in Box S1.
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Case study
The study involves a secondary analysis of a cross-sectional cohort study. Data from consecutive patients (selected for surgery) were prospectively collected for the development of risk models for general malignancy. Twenty-four centres from 10 countries participated, divided into oncology centres ('tertiary referral centres with a specific gynaecology oncology unit') and other centres. Ethics approval was discussed, but a study protocol was not mentioned. The study focused on clinical and ultrasound data. For variable definitions, the authors refer to a published consensus statement. 36 No interobserver reliability information was available, but this issue was discussed. Excised tumour tissue was histologically examined at the local centre without knowledge of the ultrasound results. Tumour histology was then classified as benign, borderline, stage I ovarian cancer, stages II-IV ovarian cancer, or secondary metastatic cancer. The serum CA125 level was an optional variable that is not routinely measured in all centres. Multiple imputation was used to handle missing serum CA125 levels.
Step III: Modelling strategy Before delving into any statistical analysis, we recommend defining a modelling strategy, which is preferably pre-specified in the study protocol. 3, 4 Regression methods such as logistic (dichotomous outcomes) or Cox regression (time-to-event outcomes) are the most frequently used algorithms. One could also use flexible methods such as support vector machines (see Box S2). 37, [38] [39] [40] [41] [42] [43] [44] An important consideration is the complexity of the model relative to the available sample size (see Box S2). 3, 45 Overly complex models are often over-fitted: they perform well on the model development data, but perform poorly on new data (Table 1, pitfall 3) . 46 Recommendations are to control the ratio of the number of events to the number of variables examined, referred to as events per variable (EPV). Although EPV is a common term, it is more appropriate to consider the total number of estimated parameters (i.e., all regression coefficients, including all those considered prior to statistical variable selection) rather than just the number of variables in the final model. 3 For binary outcomes, the number of events is the number of individuals in the smallest outcome category. A minimum of 10 EPVs is frequently recommended, 47, 48 but the following is more realistic: at least 10 EPVs when the model is prespecified, although additional 'shrinkage' (see Box S2 and step IV) of model coefficients may be required, 45, 49 at least 20 EPVs to alleviate the need for shrinkage, and at least 50 EPVs when statistical variable selection is used. 4, 45, 50, 51 Research on EPV guidelines is ongoing. 52 It is common practice to use statistical variable selection to reduce the number of variables. Backwards elimination is preferred because this approach starts with a full model (i.e., includes all variables) and eliminates non-significant variables one by one. 3 Although convenient, these methods have important limitations, especially in small datasets. 3, 46, 45, 50 Owing to repeated statistical testing, such selection methods lead to overestimated coefficients (resulting in over-fitting) and overoptimistic P-values (Table 1 , pitfall 4). 53 The same is true when selecting variables based on their univariate association with the outcome, which should be avoided. 3 Statistical significance is often not the best criterion for inclusion or exclusion of predictors. Instead of pure statistical selection, a preferable strategy is to incorporate subject matter knowledge to select predictors a priori before any multivariable analysis (see Box S2). 3, 4, 54 When dealing with categorical variables, categories with little data may be combined to reduce the number of parameters. Categorising continuous variables should be avoided, because this entails a substantial loss of information. 55 To maximise predictive ability, it is advisable to assess whether the variable has a linear effect or might need a transformation (see Box S2). 3, 56 Investigations of nonlinearity should be kept within reasonable limits relative to the number of available events to avoid overly complex models (Table 1 , pitfall 5). For the same reason, it is recommended that EPVs be controlled by specifying in advance which interaction terms are known or potentially relevant, instead of testing all possible interaction terms (Box S2). 3, 4, 57, 58 Case study Data from 3511 patients collected between 1999 and 2007 were used as development data. Discussions with experienced clinicians provided information about the likely predictive value and subjectivity of different variables, leading to 10 a priori selected variables: age, serum CA125 level, maximum lesion diameter, proportion of solid tissue, number of papillary projections, family history of ovarian cancer, ascites, shadows, > 10 cyst locules and type of centre. Further backward selection was performed and nonlinearity was investigated using multivariable fractional polynomials. Interaction terms were not considered. The smallest outcome category contained 120 observations, hence there were 12 events per predictor. However, given that 17 parameters were needed when taking nonlinearity into account, there were only 7 events per parameter.
Step IV: Model fitting
Once the analysis strategy has been defined, it can be implemented. For smaller samples sizes (e.g., EPV < 20) shrinkage methods may be considered, whereby model coefficients are penalised (i.e. shrunk) to avoid overestimation of effects. 45 A common penalisation method is ridge regression. 59 
Multinomial logistic regression was used. Family history of ovarian cancer was eliminated, resulting in a model with nine predictors. Maximum lesion diameter and serum CA125 level were log-transformed, and a quadratic effect was added for the proportion of solid tissue. Shrinkage of model coefficients was applied.
Step V: Validation of model performance
The proof of the pudding is in the eating, certainly for risk models. Model performance can be evaluated on three levels (see Box 1 for an elaboration):
Discrimination assesses whether estimated risks are different for patients with and without the disease. The most well-known measure is the c-statistic, also known as the area under the receiver-operating characteristics curve (AUC) for binary outcomes (Figure 1) . It is the probability that a randomly selected patient experiencing an event has a higher predicted probability than a randomly selected patient not experiencing the event.
Calibration assesses the agreement between the predicted risks and observed event rates. This is nicely assessed using a calibration plot (Figure 2) . 4, 60, 61 In this plot, the relationship between predicted risks and observed outcomes is visualised. A model that is well calibrated will yield a curve lying on the diagonal, suggesting that predicted risks are correct: e.g., among patients with a predicted risk of 30%, 3 out of 10 have the event. The curve in Figure 2 suggests some underestimation of predicted risks. Discrimination and calibration do not address the clinical consequences of using a risk model. [62] [63] [64] One measure to assess the clinical utility for decision making is the net benefit (NB), which is plotted in a decision curve (Figure 3) . 65, 66 NB relies on the relationship between the risk threshold and the relative importance of true vs false positives: when a risk threshold of 10% (odds 1:9) is adopted to select patients for treatment, this is equivalent to accepting up to 9 false positives (FP) per true positive (TP). NB equals the net proportion of TPs: (#TP -(1/9)*#FP)/N for a 10% risk threshold. The decision curve plots NB for different risk thresholds. The NB of the model can be compared with the NB of treating all patients or treating no patients (see Figure 3) ; if the model has higher NB at a given threshold, this means that treatment decisions at that threshold have utility.
The model is usually evaluated first with internal validation, which involves an independent assessment using the dataset that was used to develop the model. 67 The most popular approach is to randomly split the dataset into a development set and a validation set. However, this approach is inefficient and should be avoided, especially in studies with small sample sizes ( Table 1, . Circle: NB of ADNEX at threshold probability of 10%. NB is computed at various risk thresholds. If the probability of malignant disease predicted by ADNEX is higher than the risk threshold, the tumour is classified as malignant. Higher NB values indicate more clinical utility. E.g. at threshold 10% and compared to classifying no tumours as malignant, the use of ADNEX leads to the equivalent of a net 37 (NB = 0.37) correctly identified malignancies per 100 patients, without an increase in the number of benign lesions classified as malignancies. Moreover, the NB of ADNEX is 0.033 greater than assuming all tumours are malignant. This is equivalent to a net 29 (= 0.33*100/(10/90)) fewer benign lesions classified as malignancies per 100 patients, compared to classifying all as malignant.
Box 1. Validation of performance: technical details
Risk models vs classification rules
The use of a risk threshold turns the risk model into a classification (or decision) rule. Thresholds can be selected in several ways. 85, 86 At the level of the individual patient, the relative consequences of a false positive and false negative can be taken into account. For example, a threshold below 50% indicates that a false negative is considered more harmful than a false positive. At the population level, a balance in terms of sensitivity and specificity may be sought. This framework is more useful for cost-effectiveness studies and for national guidelines that formulate recommendations for clinical practice. When a threshold is defined, patient classification and actual disease status can be cross-tabulated and summarised with measures such as sensitivity, specificity, positive predictive value and negative predictive value. The positive and negative predictive values directly depend on event rate (i.e., prevalence of diagnostic outcomes), however in practice sensitivity and specificity also vary with event rate. 87 
Calibration
Calibration plots are used to check whether predicted risks correspond to observed event rates. 4, 60 They can be supplemented with estimates of the calibration slope and intercept. 4, 88 The Hosmer-Lemeshow test is frequently used but assesses neither direction nor magnitude of (mis)calibration, and suffers from serious drawbacks such as low power. Its use is therefore widely discouraged. 89, 90 Clinical utility Despite having only recently been introduced, measures for clinical utility have already been recommended by several leading journals. 66, 71, [91] [92] [93] [94] Poor discrimination and miscalibration reduce clinical utility, but good discrimination and calibration do not guarantee utility. 95 However, measures for clinical utility are not always of interest. For example, a risk model to merely inform pregnant couples of the chance of a successful pregnancy beyond the first trimester 58 would not require an analysis of clinical utility, as no decision needs to be made. Calibration is the key measure in such contexts.
Model comparison
Models can be compared by calculating the difference in the cstatistic, by comparing calibration and by comparing NB or another metric for clinical usefulness. 76 The significance of an added predictor can be based on a test for the predictor's regression coefficient rather than on tests for performance improvement (e.g. change in AUC). 96 Reclassification statistics such as net reclassification improvement (NRI) and integrated discrimination improvement (IDI) have fuelled intense debate. [97] [98] [99] We advise caution when using NRI and IDI, because they depend on calibration in the sense that models may appear advantageous simply because of poor calibration. [100] [101] [102] are recommended. 68 Publications describing the development of new risk models should always include an internal validation, 2,69 but sometimes models are immediately validated externally, i.e., evaluated on a different dataset that is collected at a different time point and/or at a different location (see below). 67 Assessment of discrimination and detecting lack of model fit using flexible calibration curves 61 are important considerations at internal validation, while calibration 61 and the assessment of clinical utility are important at external validation.
Case study
The original publication contained a temporal validation of the model, using data from 2403 patients collected between 2009 and 2012. The validation AUC for overall malignancy was 0.94. Sensitivity and specificity were reported for different risk cut-offs. A multinomial extension of the AUC was used, and the AUCs to discriminate between each pair of outcome categories varied between 0.71 and 0.95. The calibration curves on the validation data suggested adequate risk calibration. Clinical utility was not assessed, as procedures for multinomial outcomes do not exist yet.
Step VI: Model presentation and interpretation
The exact formula of the model (including the intercept or baseline survival at a given time point) should always be reported in the publication to allow independent users to validate or use it. 2, 70 To aid uptake of risk models, they are often simplified or presented in alternative formats, including score charts, nomograms or colour bars. 3, 4, 58, 71, 72 Clear eligibility criteria should be presented along with the model, including ranges of continuous predictors, so that users are made aware if they are extrapolating beyond the ranges observed in the development data.
Odds ratios were presented, and the complete formula of the model was provided in the online supplementary material. Predictor ranges were not available, only interquartile ranges.
Step VII: Model reporting [6] [7] [8] 73 This led to comprehensive guidelines and checklists for manuscript preparation, such as the recent TRIPOD statement.
2,69
Case study TRIPOD guidelines were not available at the time of publication.
Step VIII: External validation
The real test of a model involves external validation with new data, either collected at a later point in time from the same centre(s) (temporal validation) or collected at different centres (geographical validation). 67, 74 However, it is disappointing that there are many more publications describing the development of new risk models rather than externally validating existing models (Table 1, pitfall 8) . 8, 24, 75 It is better to develop fewer models that hold more promise of being robust and useful. In addition, when several models for the same purpose exist, it is recommended that these models be directly compared in a single external validation study. 76 Details on external validation are provided in Box 2.
Case study
The study immediately included an external (temporal) validation of the model.
Step IX: Impact studies
The ultimate aim of many risk models is to improve patient care. Therefore, the final step would be an impact study, perhaps together with a cost-effectiveness analysis. 24, 77, 78 Ideally, impact studies are (cluster) randomised studies for which primary endpoints are clinical care parameters such as length of hospitalization, number of unnecessary operations, days off work, time to diagnosis, morbidity or quality of
Box 2. External validation: technical details
External validation
A reliable external validation study requires a sufficiently large sample size. At least 100 but preferably 200 events are recommended. 61, 90, 103, 104 External validation often results in poorer performance. 75 There are many factors that can explain results at external validation, therefore these results have to be interpreted carefully, often in the context of differences in casemix between the development and validation datasets. 105, 106 For example, discrimination is typically lower in more homogeneous populations. Even temporal validation may show performance degradation, for example because the centre changed from a secondary to a tertiary care centre, or because new clinical guidelines have changed the population.
life. 77, 79, 80 Unfortunately, few risk models reach this stage of investigation, 24, 77 although predictive performance is no guarantee of a beneficial impact on patient outcomes. 81, 82 Case study Not yet performed, because the model should first be sufficiently validated.
Step X: Model implementation
To increase the uptake of a model, a user-friendly implementation can be provided. 83 The model can, for example, be implemented in a spreadsheet for use with office software, or made accessible on websites (e.g. www.qrisk.org). With the increasing use of smartphones and tablets, implementation is currently shifting towards mobile applications. Nevertheless, disseminating insufficiently validated risk models must be avoided.
Case study
Online and mobile applications are available (www.iotagroup.org/adnexmodel/). This group later published about the clinical use of the ADNEX model. 84 
Conclusion
The development and validation of risk models should be appropriately planned, conducted, presented and reported. Risk models should only be developed when there is a clinical need, and external validation studies should be given the attention and prominence they deserve. The development of a robust model and an informative validation are not straightforward, with several pitfalls looming along the way. Perfection is impossible, but adhering to current methodological standards is important to arrive at a good model that has the potential to be useful in clinical practice.
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